##### Table of Contents



SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
   FORM 10-Q þ
    
    Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934For the quarterly period ended March 31, 2005o
    
    Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934For the transition period from  toCommission file number 1-9957
 Diagnostic Products Corporation  California
    
    95-2802182(State or other jurisdiction of
    
    (IRS Employerincorporation or organization)
    
    Identification No.)
 5210 Pacific Concourse Drive
Los Angeles, California 90045
(Address of principal executive offices) Registrants telephone number: (310) 645-8200 No change (Former name, former address, and former fiscal year, if changed since last report) Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act
Rule 12b-2). þ o
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports) and (2) has been subject
to such filing requirements for the past 90 days. þ o
 The number of shares of Common Stock, no par value, outstanding as of April 29, 2005, was
29,311,746.




---



TABLE OF CONTENTS  PART I. FINANCIAL INFORMATIONITEM I. FINANCIAL STATEMENTSITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKITEM 4. CONTROLS AND PROCEDURESPART II. OTHER INFORMATIONItem 5. Other InformationITEM 6. EXHIBITS AND REPORTS ON FORM 8-KSIGNATURESEXHIBIT INDEXExhibit 10.1Exhibit 31.1Exhibit 31.2Exhibit 32.1    Table of Contents  
 PART I. FINANCIAL INFORMATION 
 ITEM I. FINANCIAL STATEMENTS DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited) Three Months EndedMarch 31,(Amounts in Thousands, Except Per Share Data)
    
    2005
    
    
    2004SALES:Non-Affiliated Customers
    
    $
    107,063
    
    
    $
    96,974Unconsolidated Affiliates
    
    
    5,848
    
    
    
    9,109Total Sales
    
    
    112,911
    
    
    
    106,083COST OF SALES
    
    
    46,738
    
    
    
    46,022Gross Profit
    
    
    66,173
    
    
    
    60,061OPERATING EXPENSES:Selling
    
    
    20,611
    
    
    
    18,727Research and Development
    
    
    12,266
    
    
    
    11,424General and Administrative
    
    
    12,556
    
    
    
    9,665Equity in Income of Affiliates
    
    
    (2,553
    )
    
    
    (2,130
    )OPERATING EXPENSES-NET
    
    
    42,880
    
    
    
    37,686OPERATING INCOME
    
    
    23,293
    
    
    
    22,375Interest/Other Income (Expense)-Net
    
    
    174
    
    
    
    (369
    )INCOME BEFORE INCOME TAXES
AND MINORITY INTEREST
    
    
    23,467
    
    
    
    22,006PROVISION FOR INCOME TAXES
    
    
    6,993
    
    
    
    6,602MINORITY INTEREST
    
    
    340
    
    
    
    (53
    )NET INCOME
    
    $
    16,134
    
    
    $
    15,457EARNINGS PER SHARE:BASIC
    
    $
    0.55
    
    
    $
    0.53DILUTED
    
    $
    0.54
    
    
    $
    0.52WEIGHTED AVERAGE SHARES OUTSTANDING:BASIC
    
    
    29,274
    
    
    
    28,972DILUTED
    
    
    30,105
    
    
    
    29,944DIVIDENDS DECLARED PER SHARE
    
    $
    0.07
    
    
    $
    0.06
 SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 2




---



##### Table of Contents



DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited) March 31,
    
    
    December 31,(Amounts in Thousands, Except Share Data)
    
    2005
    
    
    2004AssetsCURRENT ASSETS:Cash and cash equivalents
    
    $
    81,064
    
    
    $
    80,425Accounts receivable (including receivables from unconsolidated
affiliates of $7,925 and $6,190 respectively)  net of
allowance
for doubtful accounts of $3,604 and $3,667 respectively
    
    
    101,266
    
    
    
    100,094Inventories
    
    
    94,231
    
    
    
    93,228Prepaid expenses and other current assets
    
    
    6,507
    
    
    
    5,297Deferred income taxes
    
    
    3,902
    
    
    
    4,030Total current assets
    
    
    286,970
    
    
    
    283,074PROPERTY,
PLANT, AND EQUIPMENT - net
    
    
    149,189
    
    
    
    144,772INSTRUMENTS  net
    
    
    79,954
    
    
    
    82,730INVESTMENTS IN AFFILIATED COMPANIES
    
    
    38,669
    
    
    
    39,227OTHER ASSETS  net
    
    
    12,630
    
    
    
    11,937GOODWILL
    
    
    13,420
    
    
    
    13,441TOTAL ASSETS
    
    $
    580,832
    
    
    $
    575,181Liabilities and Shareholders EquityCURRENT LIABILITIES:Notes payable
    
    $
    2,770
    
    
    $
    4,145Accounts payable
    
    
    23,568
    
    
    
    18,391Accrued liabilities
    
    
    35,920
    
    
    
    45,644Income taxes payable
    
    
    5,839
    
    
    
    3,872Total current liabilities
    
    
    68,097
    
    
    
    72,052LONG-TERM LIABILITIES
    
    
    8,648
    
    
    
    8,846DEFERRED INCOME TAXES
    
    
    6,101
    
    
    
    5,841MINORITY INTEREST
    
    
    4,550
    
    
    
    4,210SHAREHOLDERS EQUITY:Common Stockno par value, authorized 60,000,000 shares
at March 31, 2005 and December 31, 2004; outstanding
29,298,046 shares and 29,230,196 shares, respectively
    
    
    75,794
    
    
    
    73,881Retained earnings
    
    
    404,682
    
    
    
    390,597Unrealized gains (losses) on foreign exchange contracts
    
    
    50
    
    
    
    (500
    )Cumulative foreign currency translation adjustment
    
    
    12,910
    
    
    
    20,254Total shareholders equity
    
    
    493,436
    
    
    
    484,232TOTAL LIABILITIES AND SHAREHOLDERS EQUITY
    
    $
    580,832
    
    
    $
    575,181
 SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 3




---



##### Table of Contents



DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited) Three Months EndedMarch 31,(Amounts in Thousands)
    
    2005
    
    
    2004CASH FLOWS FROM OPERATING ACTIVITIESNet income
    
    $
    16,134
    
    
    $
    15,457Adjustments to reconcile net income to net cash
flows from operating activities:Depreciation and amortization
    
    
    12,085
    
    
    
    7,774Provision for doubtful accounts
    
    
    17
    
    
    
    231Minority interest
    
    
    340
    
    
    
    (53
    )Equity in undistributed income of unconsolidated affiliates  net
of distributions
    
    
    (1,270
    )
    
    
    (1,787
    )Deferred income taxes
    
    
    188
    
    
    
    260Income tax benefit received upon exercise of stock options
    
    
    621
    
    
    
    Changes in operating assets and liabilities:Accounts receivable
    
    
    (4,035
    )
    
    
    (8,860
    )Inventories
    
    
    (9,441
    )
    
    
    (2,426
    )Prepaid expenses and other assets
    
    
    (1,387
    )
    
    
    (3,867
    )Accounts payable
    
    
    6,613
    
    
    
    1,926Accrued liabilities
    
    
    (9,219
    )
    
    
    (1,946
    )Income taxes payable
    
    
    2,122
    
    
    
    1,133Net cash flows from operating activities
    
    
    12,768
    
    
    
    7,842CASH FLOWS USED FOR INVESTING ACTIVITIES:Additions to property, plant, and equipment
    
    
    (9,651
    )
    
    
    (9,744
    )Net cash flows used for investing activities
    
    
    (9,651
    )
    
    
    (9,744
    )CASH FLOWS USED FOR FINANCING ACTIVITIESBorrowings under notes payable
    
    
    470
    
    
    
    4,250Repayments of notes payable
    
    
    (1,669
    )
    
    
    (6,503
    )Proceeds from exercise of stock options
    
    
    1,292
    
    
    
    2,358Cash dividends paid
    
    
    (2,049
    )
    
    
    (1,737
    )Net cash flows used for financing activities
    
    
    (1,956
    )
    
    
    (1,632
    )EFFECT OF EXCHANGE RATE CHANGES ON CASH
    
    
    (522
    )
    
    
    98NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    
    
    639
    
    
    
    (3,436
    )CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
    
    
    80,425
    
    
    
    69,843CASH AND CASH EQUIVALENTS AT END OF PERIOD
    
    $
    81,064
    
    
    $
    66,407SUPPLEMENTAL CASH FLOW INFORMATION -Non cash transactions  instrument placements transferred from
inventories
    
    $
    7,441
    
    
    $
    3,012Cash paid during the period for income taxes
    
    $
    4,402
    
    
    $
    5,689Cash paid during the period for interest, net of capitalized interest
    
    $
    276
    
    
    $
    401
 SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 4




---



##### Table of Contents



DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited) Note 1  Basis of Presentation The information for the three months ended March 31, 2005 and 2004 has not been audited by
independent registered public accountants, but includes all adjustments (consisting of normal
recurring accruals) that are, in the opinion of management, necessary to a fair statement of the
results for such periods. Certain information and footnote disclosure normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States of America have been
omitted pursuant to the requirements of the Securities and Exchange Commission, although the
Company believes that the disclosures included in these financial statements are adequate to make
the information not misleading. The consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Companys 2004 Annual Report on Form 10-K as filed
with the Securities and Exchange Commission. The results of operations for the three months ended March 31, 2005 are not necessarily indicative
of the results to be expected for the year ending December 31, 2005. Basic earnings per share is
computed by dividing net income by the weighted-average number of shares outstanding. Diluted
earnings per share include the dilutive effect of stock options. Certain reclassifications have been made to the 2004 periods to conform to the 2005 presentation. Note 2  Pro Forma Stock-Based Compensation Stock options issued by the Company are accounted for in accordance with Accounting Principles
Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25) as permitted by SFAS
No. 123, Accounting for Stock-Based Compensation. The Company follows the disclosure
requirements of SFAS No. 123, as amended by SFAS No. 148, Accounting for Stock-Based
CompensationTransition and Disclosure, an amendment of FASB Statement No. 123, which provides
alternative methods of transition for a voluntary change to the fair value based method of
accounting for stock-based employee compensation, and amends the disclosure requirements of SFAS
No. 123 to require prominent disclosures in both annual and interim financial statements about the
method of accounting for stock-based employee compensation and the effect of the method used on
reported results. As permitted by SFAS No. 123, the Company has chosen to continue accounting for stock options at
their intrinsic value. Accordingly, no compensation expense has been recognized for its stock
option compensation plans as all options granted had an exercise price equal to the market value of
the underlying common stock on the date of grant. Had the fair value method of accounting been
applied to the Companys stock option plans, the tax-effected impact would be as follows: 5




---



##### Table of Contents



Three Months EndedMarch 31,(Amounts in Thousand, Except Per Share Data)
    
    2005
    
    
    2004Net Income:As Reported
    
    $
    16,134
    
    
    $
    15,457Pro Forma expense, net of tax
    
    
    (782
    )
    
    
    (673
    )Pro Forma
    
    $
    15,352
    
    
    $
    14,784Net Earnings Per ShareBasic:As Reported
    
    $
    0.55
    
    
    $
    0.53Pro Forma Adjustment
    
    
    (0.03
    )
    
    
    (0.02
    )Pro Forma
    
    $
    0.52
    
    
    $
    0.51Diluted:As Reported
    
    $
    0.54
    
    
    $
    0.52Pro Forma Adjustment
    
    
    (0.03
    )
    
    
    (0.03
    )Pro Forma
    
    $
    0.51
    
    
    $
    0.49
 Note 3  Inventories Inventories by major categories are summarized as follows: March 31,
    
    
    December 31,(Amounts in Thousands)
    
    2005
    
    
    2004Raw materials
    
    $
    41,880
    
    
    $
    43,899Work in process
    
    
    34,395
    
    
    
    32,767Finished goods
    
    
    17,956
    
    
    
    16,562Total
    
    $
    94,231
    
    
    $
    93,228
 Note 4  Property, Plant & Equipment Property, plant and equipment consists of the following: March 31,
    
    
    December 31,
    
    
    Estimated(Amounts in Thousands)
    
    2005
    
    
    2004
    
    
    Useful LivesLand and buildings
    
    $
    112,163
    
    
    $
    114,552
    
    

    20-50 YearsMachinery and equipment
    
    
    111,188
    
    
    
    104,245
    
    
    3-5 YearsLeasehold improvements
    
    
    9,769
    
    
    
    9,578
    
    
    3-9 YearsConstruction in progress
    
    
    7,284
    
    
    
    3,714Total
    
    
    240,404
    
    
    
    232,089Accumulated depreciation and amortization
    
    
    (91,215
    )
    
    
    (87,317
    )Property, plant and equipment  net
    
    $
    149,189
    
    
    $
    144,772
 Construction in progress at March 31, 2005 and December 31, 2004 primarily represents the
construction and fit out of an expansion of a building in New Jersey and equipment in process of
being installed for use in operations. Capitalized interest costs were $47,000 and $269,000 in the
quarters ended March 31, 2005 and 2004, respectively. Note 5  Instruments Instruments consist of the following: 6




---



##### Table of Contents



March 31,
    
    
    December 31,(Amounts in Thousands)
    
    2005
    
    
    2004Placements and operating leases
    
    $
    227,092
    
    
    $
    227,434Less accumulated amortization
    
    
    153,085
    
    
    
    150,956Net
    
    
    74,007
    
    
    
    76,478Sales-type leases
    
    
    7,098
    
    
    
    7,234Less current portion
    
    
    1,151
    
    
    
    982Net
    
    
    5,947
    
    
    
    6,252Total
    
    $
    79,954
    
    
    $
    82,730
 Note 6  Other Assets Other assets consist of the following: March 31,
    
    
    December 31,(Amounts in Thousands)
    
    2005
    
    
    2004Long-term accounts receivable
    
    $
    5,437
    
    
    $
    4,637Purchased technology licenses
    
    
    8,136
    
    
    
    8,017Less accumulated amortization
of purchased technology
licenses
    
    
    (943
    )
    
    
    (717
    )Total
    
    $
    12,630
    
    
    $
    11,937
 Amortization expense for the three months ended March 31, 2005 and 2004 totaled $226,000 and
$166,000, respectively. Amortization expense for each of the next five fiscal years is estimated
to be $700,000 and will be amortized using the straight-line method over the shorter of their
estimated useful life or the expiration of the license. The technology license had an average
amortization period of 13 years. Note 7  Comprehensive Income Comprehensive income is summarized as follows: Three Months EndedMarch 31,(Amounts in Thousands)
    
    2005
    
    
    2004Net income
    
    $
    16,134
    
    
    $
    15,457Foreign currency translation adjustment
    
    
    (7,344
    )
    
    
    (638
    )Unrealized gain on foreign exchange contracts
net of tax impact
    
    
    550
    
    
    
    1,636Comprehensive income
    
    $
    9,340
    
    
    $
    16,455
 The Company does not provide for U.S. income taxes on foreign currency translation adjustments
because it does not provide for such taxes on undistributed earnings of foreign subsidiaries as
they have been determined to be indefinitely invested. In the event the Company decides to
repatriate the undistributed earnings of its foreign subsidiaries, the Company believes it would
have foreign tax credits available to substantially offset the additional tax. Note 8  Earnings per Share Net income as presented in the consolidated income statement is used as the numerator in the EPS
calculation for both the basic and diluted computations. The following table is a reconciliation of
the weighted-average shares used in the computation of basic and diluted Earnings Per Share (EPS)
for the income statements presented herein. 7




---



##### Table of Contents



Three Months EndedMarch 31,(Shares in Thousands)
    
    2005
    
    
    2004Basic Shares
    
    
    29,274
    
    
    
    28,972Assumed exercise of stock options
    
    
    831
    
    
    
    972Diluted Shares
    
    
    30,105
    
    
    
    29,944
 Stock options to purchase 57,000 shares of common stock in the first quarter 2005 and 29,000
shares of common stock in the first quarter 2004 were outstanding but not included in the
computation of diluted earnings per common share because the option price was greater than the
average market price of the common shares. Note 8  Segment and Product Line Information The Company considers its manufactured instruments and medical immunodiagnostic test kits to be one
operating segment as defined under SFAS No. 131, Disclosures about Segments of an Enterprise and
Related Information, as the kits are required to run the instruments and utilize similar
technology and instrument manufacturing processes. The Company manufactures its instruments and
kits principally at facilities located in the United States and the United Kingdom. Kits and
instruments are sold to hospitals, medical centers, clinics, physicians, and other clinical
laboratories throughout the world through a network of distributors, including consolidated
distributors located in the United Kingdom, Germany, Czech Republic, Poland, Slovenia, Slovakia,
Croatia, Spain, The Netherlands, Belgium, Sweden, Denmark, Norway, Finland, Latvia, Lithuania,
Estonia, France, Australia, New Zealand, China, Brazil, Costa Rica, Venezuela, Uruguay, Bolivia,
Honduras, Guatemala and Panama. The Company sells its instruments and immunodiagnostic test kits
under several product lines. Product line sales information is as follows: Three Months EndedMarch 31,(Amounts in Thousands)
    
    2005
    
    
    2004Sales:IMMULITE (includes service)
    
    $
    103,445
    
    
    $
    96,266Radioimmunoassay (RIA)
    
    
    5,591
    
    
    
    6,405Other (Includes DPC and non-DPC products)
    
    
    3,875
    
    
    
    3,412$
    112,911
    
    
    $
    106,083
 The Company is organized and managed by geographic area. Transactions between geographic
segments are accounted for as normal sales for internal reporting and management purposes with all
inter-company amounts eliminated in consolidation. Sales are attributed to geographic area based
on the location from which the instrument or kit is shipped to the customer. Information reviewed
by the Companys chief operating decision maker on significant geographic segments, as defined
under SFAS No. 131, is prepared on the same basis as the consolidated financial statements and is
provided in the following tables. Items listed in Other represent those geographic locations
that are individually insignificant. Euro/DPC
    
    
    DPC
    
    
    DPCLimited
    
    
    Biermann
    
    
    Medlab
    
    
    
    
    
    
    Less:United
    
    
    (United
    
    
    (German
    
    
    (Brazilian
    
    
    
    
    
    
    Intersegment(Amounts in Thousands)
    
    States
    
    
    Kingdom)
    
    
    Group )*
    
    
    Group )*
    
    
    Other
    
    
    Elimination
    
    
    TotalSales
    
    $
    71,220
    
    
    $
    21,438
    
    
    $
    16,159
    
    
    $
    11,272
    
    
    $
    25,697
    
    
    $
    (32,875
    )
    
    $
    112,911Net income
    
    $
    7,321
    
    
    $
    4,655
    
    
    $
    725
    
    
    $
    773
    
    
    $
    2,940
    
    
    $
    (280
    )
    
    $
    16,134Three Months Ended March 31, 2004Sales
    
    $
    65,172
    
    
    $
    20,611
    
    
    $
    14,552
    
    
    $
    7,852
    
    
    $
    25,013
    
    
    $
    (27,117
    )
    
    $
    106,083Net income
    
    $
    7,301
    
    
    $
    4,747
    
    
    $
    680
    
    
    $
    (121
    )
    
    $
    2,744
    
    
    $
    106
    
    
    $
    15,457
 *DPC Biermann includes the Companys operations in Germany, the Germany, Czech Republic,
Poland, Slovenia, Slovakia and Croatia. DPC Medlab includes the Companys operations in Brazil,
Costa Rica, Venezuela, Uruguay, Bolivia, Honduras, Guatemala and Panama. Germany and Brazil
account for the most significant portion of sales and net income for their respective groups.
 8




---



##### Table of Contents



Note 10  New Accounting Pronouncements In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123 (revised
2004) (FASB 123R), Shared Based Payment. This standard will require the Company to measure the
cost of
employee services received in exchange for an award of equity instruments based on a grant-date
fair value of the award (with limited exceptions), and that cost will be recognized over the
vesting period. The Company is required to adopt the provisions of FASB 123R effective as of
January 1, 2006. The Company is currently evaluating the financial impact, including the available
alternatives of adoption. In December 2004, the FASB issued FSP 109-2, Accounting and Disclosure Guidance for the Foreign
Earnings Repatriation Provision within the American Jobs Creation Act of 2004. The FASB staff
believes that the lack of clarification of certain provisions of the Act and the timing of its
enactment necessitate a practical exemption to the FAS 109 requirement to reflect in the period of
enactment the effect of a new tax law. Accordingly, an enterprise is allowed time beyond the
financial reporting period of enactment to evaluate the effect of the Act on its plan for
reinvestment or repatriation of foreign earnings for purposes of applying FAS 109. Whether the
Company will ultimately take advantage of this provision depends on a number of factors, including
reviewing future Congressional guidance before making a decision. The Company expects to complete
its evaluation no later than September 30, 2005. Note 11  Commitments and Contingent Liabilities In the fourth quarter of fiscal year 2002, the Company discovered internally that certain senior
managers and other employees of its Chinese subsidiary had made certain improper payments that may
have violated foreign and U.S. laws. Beginning in the early 1990s, the Chinese subsidiary made cash
payments and provided in kind benefits to hospital and laboratory customers of the Chinese
subsidiary and to employees of such customers. Because certain of the customers were state owned
enterprises and the payments may have been for the purpose, or may have had the effect, of causing
those customers to purchase products from the Chinese subsidiary, these payments and benefits may
have violated the U.S. Foreign Corrupt Practices Act as well as certain domestic Chinese laws. In
addition, the deduction of these payments and benefits by the subsidiary on its tax returns may
have been improper under the Chinese tax law, resulting in underpayments of Chinese taxes. An independent investigation by the Companys audit committee concluded that no current members of
the Companys senior management knew of or were involved in the provision of the payments and
benefits. The Company has made changes in the management of the Chinese subsidiary, including
replacement of the senior managers involved, and has implemented procedures and controls to address
these issues and to promote compliance with applicable laws. The Company voluntarily disclosed
these payment issues to the Securities and Exchange Commission (SEC) and the Department of Justice
(DOJ) in the first quarter of 2003 and has been cooperating fully with these agencies in their
investigations since that time. The Companys discussions with both the SEC and the DOJ are at advanced stages and include
proposals that the Company pay an aggregate of approximately $4.8 million to those agencies,
consisting of $2.0 million in fines and approximately $2.8 million in disgorgement of profits and
related interest charges. The proposals being discussed also include changes to the Companys
compliance programs, independent monitoring of and reporting on those programs for up to 36 months,
entry of a cease and desist order and a plea by the Companys Chinese subsidiary. Any settlement
recommended by the staff of the SEC would be subject to approval by the Commission and any plea
agreement would be subject to court approval. In the fourth quarter of 2002, the Company accrued
$1.5 million for actual and estimated costs to resolve this matter. In the third quarter of 2004,
the Company accrued an additional $1.0 million based on its revised estimates of costs that will be
paid to the U.S. Government to resolve the matter. In the fourth quarter of 2004, the Company
accrued an additional $2.4 million, including $750,000 in interest, based on the proposed
settlements with the SEC and the DOJ. As of March 31, 2005, $4.8 million remained in the accrual.
In addition, the Company recorded a charge of $1.4 million to its 2002 fourth quarter tax provision
related to the non-deductibility of the payments in China. During the third quarter of 2003, the
Company recorded an additional charge of $0.9 million to its income tax provision for this and
other Chinese tax-related matters. Legal expenses relating to this matter of approximately
$147,000 and $33,000 have been incurred and charged to general and administrative expense during
the quarters ended March 31, 2005 and 2004, respectively. It is anticipated that legal fees for
issues related to 9




---



##### Table of Contents



China will decrease in 2005 relative to 2004. The termination of the improper
payments in China has had and may continue to have a significant adverse effect on future
operations in China because such termination could negatively influence a significant number of the
Chinese subsidiarys customers decisions as to whether to continue to do business with that
subsidiary. For the quarter ended March 31, 2005, the Chinese subsidiary had sales of $1.3 million
versus sales of $2.1 million in the first quarter 2004. In February 2004, the Company was informed by the U.S. Food and Drug Administration (FDA) that,
based on inspectional findings that included data integrity and procedural issues related solely to
the Companys application for the IMMULITE Chagas test, the Company was subject to the FDAs
Application Integrity Policy (AIP). The FDA suspended its review of all applications submitted
by the Company and will not review any future applications until the FDA determines that the
Company has resolved these issues, although studies to support future applications can be conducted
while on AIP. To address the AIP issues, the Company was audited by a third party, whose report has been
submitted to the FDA. The Company also developed and implemented a corrective action plan that was
submitted to the FDA. The FDA has accepted the Companys corrective action plan and the Company is awaiting the FDAs
inspection to verify its corrective action plan.
The Company believes that the AIP issues
will be resolved with the FDA and hopes that to occur in the next few months. The FDAs application
of the AIP to DPC does not restrict DPC from introducing new tests outside of the United States.
However, the Companys inability to introduce new tests in the United States during the pendency of
the AIP may have a negative impact on its future sales and profits. In late July 2004, the Company was served with a subpoena requiring it to produce to the Federal
grand jury for the Central District of California, documents relating to trading in the Companys
securities and the exercise of options by officers, directors and employees of the Company between
December 30, 2003 and April 1, 2004. The subpoena also seeks all documents relating to the FDAs
review of the Companys diagnostic test to detect Chagas and any audits or reviews by the FDA
between 2000 and the present relating to the Companys products. Finally, the subpoena seeks the
personnel file of a former Company employee. The Company is cooperating with the United States
Attorney and the SEC regarding these matters. An independent committee of the Board of Directors
has conducted an investigation of the trading issues and has presented its findings and conclusions
to the United States Attorney and the SEC. Although it is in the early stages of the process,
management believes the ultimate resolution of this matter will not have a material financial
impact on the Company. The Companys Brazilian subsidiary is a participant along with various other companies in a number
of lawsuits against the Brazilian Government claiming unlawful taxation. Historically the companies
involved in these suits have had limited success in having these taxes over-turned. The Company has
also purchased unused tax credits for approximately $1.0 million from an unrelated Company.
However, due to uncertainty related to the Companys ability to use these credits against its tax
liabilities, it has fully reserved against the cost of these credits. These court cases typically
take many years to be decided and the Company estimates what its most likely loss outcome will be
based on the merits of the individual cases and advice of outside counsel. As of March 31, 2005,
the Company has accrued for the amounts it believes it will have to pay. In the suit that involves
the majority of the disputed taxes, in this case sales taxes, if the courts were to rule against
the Company in all actions, it would create an additional liability of approximately $1.0 million.
In March of 2005, the Companys Brazilian subsidiary was informed by the Brazilian Government that
it believed the Company owed additional tariffs due to a change the Company made to its product
classification. The Company believes that it will prevail in this case. However, if the courts were
to rule against it, it would create an additional liability of approximately $500,000. 
 ITEM 2.  MANAGEMENTS DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-Looking Statements Except for the historical information contained herein, this report and the following discussion in
particular contain forward-looking statements (identified by the words estimate, project,
anticipate, plan, expect, intend, believe, hope, and similar expressions) that are
based upon managements current 10




---



##### Table of Contents



expectations and speak only as of the date made. These
forward-looking statements are subject to risks, uncertainties, and factors that could cause actual
results to differ materially from the results anticipated in the forward-looking statements. These
risks and uncertainties include:  -
    the Companys ability to successfully market new and existing products;-
    the Companys ability to keep abreast of technological innovations and successfully
incorporate them into new products;-
    the Companys current dependence on sole suppliers for key chemical components in the
IMMULITE assays;-
    the Companys ability to address and resolve issues relating to the FDAs Application
Integrity Policy on a timely basis;-
    the Companys ability to have new tests reviewed and approved by the FDA;-
    the risks inherent in the development and release of new products, such as delays,
unforeseen costs, technical difficulties, and regulatory approvals;-
    competitive pressures, including technological advances and patents obtained by competitors;-
    environmental risks related to substances regulated by various federal, state, and international laws;-
    currency risks based on the relative strength or weakness of the U.S. dollar;-
    domestic and foreign governmental health care regulation and cost containment measures;-
    political and economic instability in certain foreign markets;-
    changes in accounting standards promulgated by the Financial Accounting Standards
Board, the Securities and Exchange Commission, the Public Company Accounting Oversight
Board, or the American Institute of Certified Public Accountants; and-
    the effects of governmental or other actions relating to certain payments by the
Companys Chinese subsidiary. Overview DPC develops and manufactures automated diagnostic test systems and related reagent test kits that
are used by hospital, reference, and physicians office laboratories throughout the world. The
Companys principal product line, IMMULITE, is a fully automated, computer-driven modular system
that uses specialized proprietary software to provide rapid, accurate test results that reduce the
customers labor and reagent costs. The Companys immunoassay tests provide critical information
useful to physicians in the diagnosis, monitoring, management, and prevention of various diseases. DPC manufactures immunodiagnostic test kits (also called reagents or assays) using several
different technologies and assay formats. The IMMULITE instruments are closed systems, meaning
that they will not perform other manufacturers tests. Accordingly, a major factor in the
successful marketing of these systems is the ability to offer a broad menu of assays. In addition
to almost 100 IMMULITE assays, the Company sells a broad range of tests based on other technologies
that can be performed manually using the customers own laboratory equipment, such as
radioimmunoassay (RIA) and enzyme immunoassay (EIA) tests. Along with the breadth of menu, major competitive factors for the IMMULITE instruments include
time-to-results (how quickly the instrument performs the test), ease of use, and overall cost
effectiveness. Because of these competitive factors and the rapid technological developments that
characterize the industry, the Company devotes approximately 10% of its annual revenues to research
and development activities, all of which are expensed as incurred. The Companys products are sold throughout the world directly and through affiliated and
independent distributors. Historically, foreign sales (including U.S. export sales, sales to
unconsolidated affiliates and independent distributors, and sales of consolidated subsidiaries)
have accounted for more than 70% of revenues, although, since 1998, domestic sales growth has
outpaced foreign sales growth. The Company derives revenues from two principal sources: reagent (test kit) sales and IMMULITE
instrument placements. The Company recognizes sales of test kits upon shipment and transfer of
title to the customer. IMMULITE instruments are placed with customers under many different types of arrangements that
generally fall into the following categories: sale, lease, reagent rental, and soft placement. The
Company sells instruments directly to end-users, to third party leasing companies that lease the
instruments to end-users, and to independent distributors that then resell the instruments to their
customers. Instrument sales, which represent the smallest component of placements, are recognized
upon shipment and transfer of title. The Company also 11




---



##### Table of Contents



sells instruments under sales-type leases,
which are recorded as revenue upon shipment in an amount equal to the present value of the future
minimum lease payments to be received over the lease term. Many instruments are placed by other than by outright sale or sales-type leases. The Company
enters into various types of operating lease arrangements with customers that generally provide for
terms of three to five years and periodic rental payments. Revenue on these types of leases is
recognized on a pro rata basis over the
term of the lease. When an instrument is placed on a reagent rental basis, the customer agrees to
pay a mark-up on reagents, but is not charged for the instrument. The Company also places
instruments at no charge to the customer (soft placement) subject to the customers agreement to
purchase a minimum amount of reagents. In reagent rentals and soft placements, the only revenue
recognized is based on reagent shipments. Under operating lease, rental, and soft placements, DPC
continues to own the instrument that is placed with the customer. These instruments are generally
amortized on a straight-line basis over five years and maintenance costs are expensed as incurred.
The Company also enters into service contracts with customers and recognizes service revenue over
the related contract life (related costs are expensed as incurred). Two important indicators used by management to evaluate financial performance are instrument
shipments and reagent utilization. The number of IMMULITE instruments that the Company reports as
being shipped in any period is net of instruments that come back to the Company, such as returns at
the end of a lease or rental or trade-ins on the purchase of a new model. Historically, the
Company has rarely experienced sales returns. The Company refurbishes and seeks to place
instruments that come back to the Company at reduced prices. Because of the different methods in
which instruments are placed, total instrument sales vary from period to period based on the
relative mix of placement methods, and such sales do not necessarily have a direct correlation to
the number of instruments shipped during the period. An important measure of the penetration of IMMULITE reagent sales is the average amount of reagent
sales per instrument shipped. It takes a number of weeks or months after an instrument is shipped
for it to become fully functional with regard to reagent utilization because of the time it takes
for a customer to become familiar with the operation of the instrument and all of the tests a
customer can run on the instrument. The Company calculates average reagent utilization for a
fiscal period by dividing IMMULITE reagent sales for the period by the total number of instruments
shipped as of the end of the previous fiscal period. 12




---



##### Table of Contents



Results of Operations SUMMARY FINANCIAL DATA (Amounts in thousands, except for share data)
    
    Q1 2005
    
    
    % change
     
    Q1 2004Sales
    
    $
    112,911
    
    
    
    6.4
    %
    
    $
    106,083Gross Profit
    
    
    66,173
    
    
    
    
    
    
    
    60,061% of sales
    
    
    58.6
    %
    
    
    
    
    
    
    56.6
    %Operating Expenses:Selling
    
    
    20,611
    
    
    
    
    
    
    
    18,727Research and Development
    
    
    12,266
    
    
    
    
    
    
    
    11,424General and Administrative
    
    
    12,556
    
    
    
    
    
    
    
    9,665Equity in Income of Affiliates
    
    
    (2,553
    )
    
    
    
    
    
    
    (2,130
    )Total Operating Expenses, net
    
    
    42,880
    
    
    
    13.8
    %
    
    
    37,686% of sales
    
    
    38.0
    %
    
    
    
    
    
    
    35.5
    %Operating Income
    
    
    23,293
    
    
    
    4.1
    %
    
    
    22,375% of sales
    
    
    20.6
    %
    
    
    
    
    
    
    21.1
    %Interest/Other (Expense) Income, net
    
    
    174
    
    
    
    
    
    
    
    (369
    )Income Before Income Taxes and
Minority interest
    
    
    23,467
    
    
    
    
    
    
    
    22,006Provision for Income Taxes
    
    
    6,993
    
    
    
    
    
    
    
    6,602Income Tax Rate
    
    
    29.8
    %
    
    
    
    
    
    
    30.0
    %Minority Interest
    
    
    340
    
    
    
    
    
    
    
    (53
    )Net Income
    
    $
    16,134
    
    
    
    4.4
    %
    
    $
    15,457Earnings per share:Basic
    
    $
    0.55
    
    
    
    
    
    
    $
    0.53Diluted
    
    $
    0.54
    
    
    
    
    
    
    $
    0.52
 Sales The Companys sales increased 6.4% in the first quarter of 2005 to $112.9 million compared to sales
of $106.1 million in the first quarter of 2004. Sales of all IMMULITE products, instruments,
service, and reagents in the first quarter of 2005 was $103.4 million, a 7.5% increase over 2004.
In the first quarter of 2005, IMMULITE products represented 92% of sales versus 91% in 2004.
Various categories of IMMULITE product line sales in the first quarter of 2005 and 2004 are shown
in the following chart: Immulite Product Line Sales(Amounts in thousands)
    
    2005
    
    
    % Change
    
    
    2004Immulite 2000/2500Reagents
    
    $
    63,865
    
    
    
    16.2
    %
    
    $
    54,977Instruments and Service
    
    
    7,944
    
    
    
    -20.6
    %
    
    
    10,009Total
    
    
    71,809
    
    
    
    10.5
    %
    
    
    64,986Immulite 1000Reagents
    
    
    26,985
    
    
    
    -0.5
    %
    
    
    27,107Instruments and Service
    
    
    4,651
    
    
    
    11.5
    %
    
    
    4,173Total
    
    
    31,636
    
    
    
    1.1
    %
    
    
    31,280Immulite Product Line Sales
    
    $
    103,445
    
    
    
    7.5
    %
    
    $
    96,266
 The Company shipped a total of 209 IMMULITE systems during the first quarter of 2005, including 139
IMMULITE 2000/2500 systems and 70 IMMULITE 1000 systems. The total base of IMMULITE systems
shipped grew to 10,219, including 3,797 IMMULITE 2000 and 2500 systems. In the first quarter of
2004 the Company shipped a total of 209 IMMULITE systems, including 158 IMMULITE 2000 systems. 13




---



##### Table of Contents



Although the number of IMMULITE 1000s shipped increased, the IMMULITE 1000 and its
predecessor system, the IMMULITE, have been available in the market over ten years and the number
of IMMULITE 1000s shipped could go down in the future. The Company also ships IMMULITE systems
that have been returned by customers and refurbished by the Company. These refurbished systems are
not included in the Companys count of units shipped. In the fourth quarter of 2003, the Company reduced the price of the IMMULITE 2000 in anticipation
of the release of the IMMULITE 2500, which occurred in June of 2004. The IMMULITE 2000/2500 has a
longer sales process than the IMMULITE 1000 due to its higher sales price, and the IMMULITE
2000/2500 experiences a longer time delay between instrument placement and the ramp-up of reagent
sales. The 2500 is targeted primarily at the hospital market because it is able to more rapidly
report certain test results, such as tests used in emergency rooms to aid in the diagnosis of
certain cardiac conditions. For this reason, although the 2500 has a higher price than the 2000,
the 2500 may erode sales of the 2000. However the two instruments are otherwise very similar and
the Company continues to market the 2000 to a significant group of customers for which the faster
test results are not critical, such as large reference laboratories. The Company has 67 tests
available for use on the IMMULITE 2500, compared to 86 on the IMMULITE 2000. Not all of these
tests have been approved by the FDA for use in the United States. The Companys ability to add
FDA-approved tests to the IMMULITE 2000/2500 menu will depend on the resolution of the FDA inquiry
discussed below. The Company is, however, able to market new tests abroad without FDA approval and
expects to introduce new tests for the IMMULITE 2500 or the IMMULITE 2000, such as Pro-BNP, Vitamin
B-12 and Folic Acid later this year. The decrease in IMMULITE 2000/2500 instrument and service revenue in the first quarter of 2005 as
compared to 2004 is due to a lower number of instruments being shipped, partially offset by an
increase in revenue from service and parts. The most significant reduction in instruments sold was
in Italy and Turkey, which decreased by 30 instruments compared to 2004. It is expected that
shipments to these entities will increase in future quarters. Included in IMMULITE 2000/2500
equipment sales is revenue relating to the Companys sample management system (SMS), a
sample-handling device that can be attached to the IMMULITE 2000/2500. The increase in IMMULITE
1000 instrument and service revenue was due to higher shipments of instruments and an increase in
service revenue. For the first quarter of 2005, IMMULITE 2000/2500 reagent utilization per instrument was $17,459
and IMMULITE reagent utilization per instrument was $4,248 as compared to the first quarter of
2004, when they were $18,674 and $4,452, respectively. The decrease in utilization on the IMMULITE
2000/2500 is in part a result of no significant new test introductions over the past year. The
Company plans to introduce a number of tests internationally and, if removed from AIP, in the
United States in the next few quarters. A drop in average utilization per instrument on the
IMMULITE is expected to continue as high volume IMMULITE installations are replaced with IMMULITE
2000s and 2500s and incremental IMMULITE placements go into lower volume environments. Sales of the Companys mature RIA products declined approximately 13% in the first quarter of 2005,
representing 5% of sales, compared to 6% of sales in the first quarter of 2004. This trend is
expected to continue. Sales of other DPC products declined to $1.3 million in the first quarter of
2005 from $1.8 million in the first quarter of 2004. The primary reason for this was a decline in
the Companys micro-plate allergy product. The Company ceased manufacturing this product line at
the end of 2003 because of the availability of allergy testing on the IMMULITE 2000. Sales of
non-DPC products, primarily through its consolidated international affiliates, increased 62% in the
first quarter of 2005 to $2.6 million and remained 2% of sales with the introduction of new
products such as a clinical chemistry system developed by Kone that is sold in certain
international markets. In the first quarter of 2005, sales to domestic customers grew by 10% to 29% of total sales. The
increase in domestic sales was due to increased penetration into most customer segments. Foreign
sales (including U.S. export sales, sales to non-consolidated foreign subsidiaries, and sales of
consolidated subsidiaries) as a percentage of total sales were approximately 71% in the first
quarter of 2005. Europe, the Companys principal foreign market, represented 45% of sales in the
first quarter of 2005 and 49% of sales in 2004. Sales in the Companys German subsidiary (DPC
Biermann), which includes the Czech Republic and Poland, increased 11% in part as a result of the
strength of the Euro. Sales in the Brazil region, which includes certain other Central and South
American countries, accounted for approximately 10% of total sales in the first quarter of 14




---



##### Table of Contents



2005, an increase of 44% over the first quarter of 2004, of which approximately 14% came from the
strengthening of the Brazilian Real relative to the U.S. dollar. In the past few years, the Real
has been very volatile relative to the dollar. Due to the significance of foreign sales, the Company is subject to currency risks based on the
relative strength or weakness of the U.S. dollar. In periods when the U.S. dollar is
strengthening, the effect of translation of financial statements of consolidated affiliates is that
of lower sales and net income. In periods where the dollar is weakening, the impact is the
reverse. Based on comparative exchange rates in the first quarter of 2005 and 2004, the dollar
weakened relative to the Euro and the Brazilian Real. The effect of the changes of exchange rates
on sales was a positive 3%. Due to intense competition, the Companys foreign distributors are
generally unable to increase prices to offset any negative effect when the U.S. dollar is strong. In the fourth quarter of fiscal year 2002, the Company discovered internally that certain senior
managers and other employees of its Chinese subsidiary had made certain improper payments that may
have violated foreign and U.S. laws. Beginning in the early 1990s, the Chinese subsidiary made cash
payments and provided in kind benefits to hospital and laboratory customers of the Chinese
subsidiary and to employees of such customers. Because certain of the customers were state owned
enterprises and the payments may have been for the purpose, or may have had the effect, of causing
those customers to purchase products from the Chinese subsidiary, these payments and benefits may
have violated the U.S. Foreign Corrupt Practices Act as well as certain domestic Chinese laws. In
addition, the deduction of these payments and benefits by the subsidiary on its tax returns may
have been improper under the Chinese tax law, resulting in underpayments of Chinese taxes. An independent investigation by the Companys audit committee concluded that no current members of
the Companys senior management knew of or were involved in the provision of the payments and
benefits. The Company has made changes in the management of the Chinese subsidiary, including
replacement of the senior managers involved, and has implemented procedures and controls to address
these issues and to promote compliance with applicable laws. The Company voluntarily disclosed
these payment issues to the Securities and Exchange Commission (SEC) and the Department of Justice
(DOJ) in the first quarter of 2003 and has been cooperating fully with these agencies in their
investigations since that time. The Companys discussions with both the SEC and the DOJ are at advanced stages and include
proposals that the Company pay an aggregate of approximately $4.8 million to those agencies,
consisting of $2.0 million in fines and approximately $2.8 million in disgorgement of profits and
related interest charges. The proposals being discussed also include changes to the Companys
compliance programs, independent monitoring of and reporting on those programs for up to 36 months,
entry of a cease and desist order and a plea by the Companys Chinese subsidiary. Any settlement
recommended by the staff of the SEC would be subject to approval by the Commission and any plea
agreement would be subject to court approval. In the fourth quarter of 2002, the Company accrued
$1.5 million for actual and estimated costs to resolve this matter. In the third quarter of 2004,
the Company accrued an additional $1.0 million based on its revised estimates of costs that will be
paid to the U.S. Government to resolve the matter. In the fourth quarter of 2004, the Company
accrued an additional $2.4 million, including $750,000 in interest, based on the proposed
settlements with the SEC and the DOJ. As of March 31, 2005, $4.8 million remained in the accrual.
In addition, the Company recorded a charge of $1.4 million to its 2002 fourth quarter tax provision
related to the non-deductibility of the payments in China. During the third quarter of 2003, the
Company recorded an additional charge of $0.9 million to its income tax provision for this and
other Chinese tax-related matters. Legal expenses relating to this matter of approximately
$147,000 and $33,000 have been incurred and charged to general and administrative expense during
the quarters ended March 31, 2005 and 2004, respectively. It is anticipated that legal fees for
issues related to China will decrease in 2005 relative to 2004. The termination of the improper
payments in China has had and may continue to have a significant adverse effect on future
operations in China because such termination could negatively influence a significant number of the
Chinese subsidiarys customers decisions as to whether to continue to do business with that
subsidiary. For the quarter ended March 31, 2005, the Chinese subsidiary had sales of $1.3 million
versus sales of $2.1 million in the first quarter 2004. In February 2004, the Company was informed by the U.S. Food and Drug Administration (FDA) that,
based on inspectional findings that included data integrity and procedural issues related solely to
the Companys application for the IMMULITE Chagas test, the Company was subject to the FDAs
Application Integrity Policy (AIP). The FDA suspended its review of all applications submitted
by the Company and will not 15




---



##### Table of Contents



review any future applications until the FDA determines that the Company has resolved these issues,
although studies to support future applications can be conducted while on AIP. To address the AIP issues, the Company was audited by a third party, whose report has been
submitted to the FDA. The Company also developed and implemented a corrective action plan that was
submitted to the FDA. The FDA has accepted the Companys corrective action plan and the Company is
awaiting the FDAs inspection to verify its corrective action plan. The Company believes that the AIP issues
will be resolved with the FDA and hopes that to occur in the next few months. The FDAs application
of the AIP to DPC does not restrict DPC from introducing new tests outside of the United States.
However, the Companys inability to introduce new tests in the United States during the pendency of
the AIP may have a negative impact on its future sales and profits. In late July 2004, the Company was served with a subpoena requiring it to produce to the Federal
grand jury for the Central District of California, documents relating to trading in the Companys
securities and the exercise of options by officers, directors and employees of the Company between
December 30, 2003 and April 1, 2004. The subpoena also seeks all documents relating to the FDAs
review of the Companys diagnostic test to detect Chagas and any audits or reviews by the FDA
between 2000 and the present relating to the Companys products. Finally, the subpoena seeks the
personnel file of a former Company employee. The Company is cooperating with the United States
Attorney and the SEC regarding these matters. An independent committee of the Board of Directors
has conducted an investigation of the trading issues and has presented its findings and conclusions
to the United States Attorney and the SEC. Although it is in the early stages of the process,
management believes the ultimate resolution of this matter will not have a material financial
impact on the Company. The Companys Brazilian subsidiary is a participant along with various other companies in a number
of lawsuits against the Brazilian Government claiming unlawful taxation. Historically the companies
involved in these suits have had limited success in having these taxes over-turned. The Company has
also purchased unused tax credits for approximately $1.0 million from an unrelated Company.
However, due to uncertainty related to the Companys ability to use these credits against its tax
liabilities, it has fully reserved against the cost of these credits. These court cases typically
take many years to be decided and the Company estimates what its most likely loss outcome will be
based on the merits of the individual cases and advice of outside counsel. As of March 31, 2005,
the Company has accrued for the amounts it believes it will have to pay. In the suit that involves
the majority of the disputed taxes, in this case sales taxes, if the courts were to rule against
the Company in all actions, it would create an additional liability of approximately $1.0 million.
In March of 2005, the Companys Brazilian subsidiary was informed by the Brazilian Government that
it believed the Company owed additional tariffs due to a change the Company made to its product
classification. The Company believes that it will prevail in this case. However, if the courts were
to rule against it, it would create an additional liability of approximately $500,000. Cost of Sales Gross margin increased to 58.6% in the first quarter of 2005 from 56.6% in the first quarter of
2004. This increase was due in part to an increase in reagent sales as a percent of total sales
and an increase in the gross margin of instruments due to an increase in the price of instruments.
This was partially offset by increased sales discounts on purchased reagents. All products
manufactured in the United States are dollar-based. However, a large percentage of these products
are sold to Company-owned international distributors, which sell the products in their local
currencies. In periods of a weakening dollar, sales as measured in dollars increase, resulting in
higher gross margins. A strengthening dollar generally results in lower gross margins at
international distributors. Operating Expenses and Other Total operating expenses (selling, research and development, and general and administrative) as a
percentage of sales increased to 38.0% in the first quarter of 2005 from 35.5% in the same period
of 2004. Selling expense increased by $1.9 million to 18.3% of sales in the first quarter of 2005.
Included in the increase is $830,000 in Germany in part related to an increase in sales commissions
due to revenue increases in Poland and increases in compensation related expenses in Germany,
$500,000 in Brazil related to the significant revenue growth in that region and $400,000 in the
United States related to increases in compensation related expenses. The weakness of the U.S.
Dollar relative to the Euro and the Real and an increase in marketing programs also contributed to 16




---



##### Table of Contents



the increase. Although research and development expense increased by about $850,000 reflecting the
Companys continuing commitment to its research efforts, it increased only slightly to 10.9% of
sales from 10.8% in 2004. General and administrative expense increased by $2.9 million to 11.1% of
sales in the first quarter of 2005 compared to 9.1% in 2004. A portion of this increase was related
to an increase in headcount and the weakness of the United States Dollar relative to the Euro and
the Real. Some of the other increases relative to the first quarter of 2004 were $225,000 in
Sarbanes Oxley Section 404 audit expenses, $235,000 in moving expenses related to the Companys new
headquarters and $170,000 in Tsunami relief matching contributions. Also included in general and
administrative expenses was $147,000 in the first quarter of 2005 and $33,000 in the first quarter
of 2004 related to the Companys internal investigation of certain payments by its Chinese
subsidiary. The review of this matter is ongoing. See Note 11 of Notes to the Consolidated
Financial Statements. Equity in income of affiliates represents the Companys share of earnings in non-consolidated
affiliates, principally the 45%-owned Italian distributor. The amount increased to $2.6 million in
2005 from $2.1 million in 2004. Interest/other (expense) income-net includes interest income, interest expense, and foreign
exchange transaction losses and gains. The net amount of income was $174,000 in the first quarter
of 2005 versus expense of $369,000 in 2004. This difference was driven in part by a $104,000
increase in foreign currency transaction losses to a loss of $310,000, offset of a $647,000 change
in interest and other expense to income of $483,000 in 2005, which was due to both an increase of
$209,000 in investment income and a decrease of $438,000 in other expense. Income Taxes and Minority Interest The Companys effective tax rate includes federal, state, and foreign taxes. The Companys tax
rate decreased to 29.8% in the first quarter of 2005 from 30.0% in the first quarter of 2004.
Minority interest represents the 44% interest in the Companys Brazilian subsidiary held by a third
party. Increases or decrease in this amount reflect increases and decreases in the profitability of
the Brazilian distributor. Net Income Net income increased 4% to $16.1 million in the first quarter of 2005 or $.54 per diluted share
from $15.5 million or $.52 per diluted share in the first quarter of 2004. Contractual Obligations and Commitments The Companys contractual obligations and commitments have not changed significantly from those
discussed in Item 7 of the Companys Annual Report on Form 10-K for the year ended December 31,
2004. Critical Accounting Policies The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Management bases its estimates and assumptions, where
applicable, on historical experience and on various other factors that it believes to be reasonable
under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities. Allowance for Bad Debts Credit is granted to customers on an unsecured basis. The Company records an allowance for
doubtful accounts at the time revenue is recognized based on the assessment of the business
environment, customers financial condition, historical collection experience, accounts receivable
aging and customer disputes. When circumstances arise or a significant event occurs that comes to
the attention of management, such as a bankruptcy filing of a customer, the allowance is reviewed
for adequacy and adjusted to reflect the change in the estimated amount to be received from the
customer. If the Companys aging of receivables balances were to deteriorate, the Company would
have to record additional provisions for doubtful accounts. 17




---



##### Table of Contents



Allowance for Obsolete and Slow-Moving Inventories Inventories are stated at the lower of cost, determined on the first-in, first-out basis, or
market. The Company regularly evaluates inventory for obsolescence and records a provision if
inventory costs are not estimated to be recoverable in the normal course of business. If the
Companys inventories were to become obsolete or slow moving, the Company would have to record
additional provisions for obsolete inventories. Property, Plant and Equipment Property, plant and equipment is stated at cost, less accumulated depreciation and
amortization, which is computed using straight-line and declining-balance methods over the
estimated useful lives (3 to 50 years) of the related assets. Leasehold improvements are amortized
over the shorter of their estimated useful lives or the term of the related lease. If the
Companys estimate of the useful life of its property, plant and equipment changes, the Company may
have to use a different life to record its depreciation and amortization. The Company reviews property, plant, and equipment for impairment whenever events or changes
in circumstance indicate that the carrying amount of an asset may not be recoverable. An
impairment loss, measured by the difference in the estimated fair value and the carrying value of
the related asset, is recognized when the future cash flows (based on undiscounted cash flows) are
less than the carrying amount of the asset. For purposes of estimating future cash flows
for possibly impaired assets, the Company groups assets at the lowest level for which there are
identifiable cash flows that are largely independent of the cash flows of other groups of assets. Goodwill and Intangible Assets Goodwill results primarily from the Companys purchase of certain of its foreign distributors.
Goodwill is tested for impairment at the reporting unit level at least annually or whenever events
or circumstances indicate that goodwill might be impaired. The evaluation requires that the
reporting unit underlying the goodwill be measured at fair value and, if this value is less than
the carrying value of the unit, a second test must be performed. Under the second test, the current
fair value of the reporting unit is allocated to the assets and liabilities of the unit, including
an amount for implied goodwill. If implied goodwill is less than the net carrying amount of
goodwill, then the difference becomes the amount of the impairment that must be recorded in that
year. The 2004 annual review did not result in any goodwill impairment for the Company.
Intangible assets consist of purchased technology licenses. The technology licenses are amortized
using the straight-line method over the shorter of their estimated useful life or the expiration of
the license. The technology license had an average amortization period of 13 years. Deferred Income Taxes Deferred income taxes represent the income tax consequences on future years of differences
between the income tax basis of assets and liabilities and their basis for financial reporting
purposes multiplied by the applicable statutory income tax rate. Valuation allowances are
established against deferred income tax assets if it is more likely than not that they will not be
realized. The Company has deferred income tax assets for state net operating loss carry-forwards
and state research and development tax credits. Such loss carry-forwards and credits expire in
accordance with provisions of applicable tax laws beginning in the years 2005 through 2011. The
Company maintains a valuation allowance for the entire net operating loss and research and
development tax credit carry-forwards as utilization of these losses and credits because it is more
likely than not that they will not be recovered. Revenue Recognition The Companys revenue recognition policies are included in Item 2. Managements Discussion
and Analysis of Financial Condition and Results of Operations  Overview. Changes in the
underlying terms of the Companys various revenue arrangements could result in changes in the
revenue recognition policies. Additionally, changes in the Companys sales returns experience
could result in the need for a sales return allowance. Contingencies The Company is involved with various legal matters for which there is uncertainty relative to
the outcome, including those involving the Companys Chinese and Brazilian subsidiaries. To
provide for the potential exposure, the Company established accruals for unfavorable rulings that
management believes are adequate. In 18




---



##### Table of Contents



addition, the Company is routinely involved in federal and state income tax audits. To
provide for potential tax exposures, the Company maintains an allowance for tax contingencies which
management believes is adequate. Liquidity and Capital Resources The Company has adequate working capital and sources of capital to carry on its current business
and to meet its existing capital requirements. At March 31, 2005 and December 31, 2004, the
Company had cash and cash equivalents of $81.1 million and $80.4 million, respectively. Net cash
flows from operating activities was $12.8 million in the first quarter of 2005, consisting of $28.1
million provided by net income ($16.1 million) adjusted for depreciation and amortization ($12.1
million), less other non-cash items ($0.1 million) included in net income, less $15.3 million used
in changes in operating assets and liabilities. The most significant elements of the net cash used
in operating assets and liabilities were a $9.4 million increase in inventories, which includes
$7.4 million in placed instruments, a $4.0 million increase in accounts receivable and a $9.2
million reduction in accrued liabilities of which $6.1 million related to the funding of the
Companys 401(K) plan. Net cash flows from operating activities was $7.8 million in the first
quarter of 2004, consisting of $22.0 million provided by net income ($15.5 million) adjusted for
depreciation and amortization ($7.8 million) less other non-cash items ($1.3 million) included in
net income, less $14.0 million used in changes in operating assets and liabilities. The most
significant elements of the net cash used in operating assets and liabilities were a $2.4 million
increase in inventories, which includes $3.0 million in placed instruments, a $8.9 million increase
in accounts receivable related to an increase in sales, a $3.8 million increase in prepaid expenses
and other assets and a $1.9 million reduction in accrued liabilities. Cash flows for investing activities consist primarily of additions to property, plant and
equipment. Additions to property, plant and equipment in both the first quarter of 2005 and 2004
were $9.7 million. In 2005 the additions were in part related to the expansion of the Companys
manufacturing facility in New Jersey, and increases in equipment in Los Angeles. In 2004 the
additions were in part related to the fit-out of the new Los Angeles corporate headquarters and the
construction of a new building in Wales, both of which were completed by the end of 2004. It is
anticipated that the Companys New Jersey expansion will be completed in the third quarter of 2005
at a cost of $9.0 million, of which approximately $4.2 million had been spent as of the end of the
first quarter. The Company decreased borrowings by $1.2 million in the first quarter of 2005 and by
$2.3 million in the first quarter of 2004. The Companys foreign operations are subject to risks,
such as currency devaluations, associated with political and economic instability. See discussion
above under Results of Operations. The Company has a $20 million unsecured line of credit with Wells Fargo Bank. No borrowings were
outstanding at March 31, 2005 or December 31, 2004 under the line of credit. The line of credit
matures July 2005, at which time the Company expects to enter into a similar borrowing agreement.
The Company had notes payable (consisting of bank borrowings by the Companys foreign consolidated
subsidiaries payable in the local currency, some of which are guaranteed by the U.S. parent
Company) of $11.0 million at March 31, 2005 compared to $13.0 million at December 31, 2004. The
Company paid a quarterly cash dividend of $.06 per share, on a split-adjusted basis, from 1995
until the fourth quarter of 2004. In the forth quarter of 2004, the Company increased its quarterly cash
dividend to $.07 per share. New Accounting Pronouncements In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123 (revised
2004) (FASB 123R), Shared Based Payment. This standard will require the Company to measure the
cost of employee services received in exchange for an award of equity instruments based on a
grant-date fair value of the award (with limited exceptions), and that cost will be recognized over
the vesting period. The Company is required to adopt the provisions of FASB 123R effective as of
January 1, 2006. The Company is currently evaluating the financial impact, including the available
alternatives of adoption. In December 2004, the FASB issued FSP 109-2, Accounting and Disclosure Guidance for the Foreign
Earnings Repatriation Provision within the American Jobs Creation Act of 2004. The FASB staff
believes that the lack of clarification of certain provisions of the Act and the timing of its
enactment necessitate a practical exemption to the FAS 109 requirement to reflect in the period of
enactment the effect of a new tax law. Accordingly, an enterprise is allowed time beyond the
financial reporting period of enactment to evaluate the effect of the Act on its plan for
reinvestment or repatriation of foreign earnings for purposes of applying FAS 109. Whether DPC
will ultimately take advantage of this provision depends on a number of factors, 19




---



##### Table of Contents



including reviewing future Congressional guidance before making a decision. The Company expects to
complete its evaluation no later than September 30, 2005. 
 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes during the quarter ended March 31, 2005, from the
disclosures about market risk provided in the Companys Annual Report on Form 10-K for the year
ended December 31, 2004. 
 ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Reporting The Companys management, with the participation of the Chief Executive Officer and Chief Financial
Officer, conducted an evaluation of the Companys disclosure controls and procedures as of March
31, 2005. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer of the
Company have concluded that such disclosure controls and procedures were adequate and effective and
designed to ensure that material information relating to the Company and its consolidated
subsidiaries would be made known to them by others within those entities. Internal Control Over Financial Reporting There has been no change in the Companys internal control over financial reporting identified in
connection with the evaluation that occurred during the Companys last fiscal quarter that has
materially affected or is reasonably likely to materially affect the Companys internal control
over financial reporting, except that the Company has implemented a new general ledger system in
its manufacturing facility in New Jersey. This general ledger system is used in the Companys other
primary manufacturing facilities. The internal controls over financial reporting included in this
application were tested for effectiveness prior to its implementation. 
 PART II. OTHER INFORMATION 
 Item 5. Other Information In April 2005, the Company exercised an option to extend a lease for a portion of its Los
Angeles offices with a partnership comprised of Michael Ziering, Ira Ziering and Marilyn Ziering,
directors and/or executive officers of the Company, and other family members who are shareholders
of the Company. The option extends the term of the lease for two years from January 1, 2005
through December 31, 2006 at an annual rent of $1,086,744. The Companys independent directors
unanimously approved the exercise of the option after considering two independent appraisals. 
 ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 10.1 Standard Industrial Lease Option Exercise dated as of January 1, 2005, between
Diagnostic Products Corporation and 5700 W. 96th Street, a general partnership.
31.1 Certificate of Chief Executive Officer
31.2 Certificate of Chief Financial Officer
32.1 Section 906 Officers Certification 20




---



##### Table of Contents



SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DIAGNOSTIC PRODUCTS CORPORATION
(Registrant) /s/ Michael Ziering
    
    Chief Executive Officer and
    
    May 10, 2005Chairman of the BoardMichael Ziering
    
    (Principal Executive Officer)Director/s/ James L. Brill
    
    Vice President-Finance
    
    May 10, 2005(Principal Financial andJames L. Brill
    
    Accounting Officer)
 21




---



##### Table of Contents



EXHIBIT INDEX 10.1 Standard Industrial Lease Option Exercise dated as of January 1, 2005, between
Diagnostic Products Corporation and 5700 W. 96th Street, a general partnership.
31.1 Certificate of Chief Executive Officer
31.2 Certificate of Chief Financial Officer
32.1 Section 906 Officers Certification 22